Breaking News

Bayer MaterialScience Invests in High-Tech Products for Medical Technology

By Tim Wright | November 25, 2009

Bayer MaterialScience has entered into an agreement to acquire PolyBioMed Ltd. based in Sheffield, UK, expanding its product portfolio for medical technology.

Bayer MaterialScience has entered into an agreement to acquire PolyBioMed Ltd. based in Sheffield, UK, expanding its product portfolio for medical technology. PolyBioMed, a subsidiary of Lombard Medical Technologies plc, provides polymer coatings, surface treatments and biomaterials to the medical device industry. The acquisition gives Bayer MaterialScience access to application areas such as coronary drug-eluting stents plus catheter systems for interventional cardiology, urology and neurology. The aim is to provide innovative materials which can enhance design, manufacturing and end-use performance for a variety of medical devices. Bayer MaterialScience is looking to further develop its own polyurethane-based hydrophilic coatings for medical devices with PolyBioMed's technologies to offer an extended portfolio of permanent and biodegradable surface modification techniques.

"This acquisition complements our existing portfolio of coatings technologies for the medical device industry and offers us a significant foothold in this large and growing segment," said Dr. Hans-Wilhelm Engels, senior vice president, coatings, adhesives and specialties, Bayer MaterialScience. "We will be investing further in coatings application and testing facilities which will significantly expand our services to customers."

Included in the intellectual property Bayer MaterialScience has acquired are the rights to over 75 patents and patent applications. "Acquiring PolyBioMed's coatings and surface treatment technologies will allow us to address unmet needs such as improved coatings adhesion on plastics or metal surfaces used in many medical devices," said Dr. Michael Mager, head of medical coatings and adhesives, Bayer MaterialScience.

blog comments powered by Disqus